The company lacks a sustainable commercial foundation, evidenced by the absence of consistent top-line growth and quarterly operating losses that frequently exceed $15 million.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 190K | 190K | 235K | 353K | 10.39M | 0 | 10.46M | 422K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | -19.15% | -33.43% | -96.6% | - | -100% | 2377.49% | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 22.52M | 1.55M | 0 | 0 | 1.7M | 1.3M | 17.29M | 14.05M | 746K | 713K | 900K | 0 | 0 | 0 | 540K |
| COGS % of Revenue | - | 817.37% | - | - | 16.32% | - | 165.38% | 3328.91% | - | - | - | - | - | - | - |
| Gross Profit | -22.33M | -1.36M | 235K | 353K | 8.69M | -1.3M | -6.84M | -13.63M | -746K | -713K | -900K | 0 | 0 | 0 | -540K |
| Gross Margin % | -11754.74% | -717.37% | 100% | 100% | 83.68% | - | -65.39% | -3228.91% | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -680% | -33.43% | -95.94% | 766.49% | 80.92% | 49.83% | -1726.54% | -4.63% | 20.78% | - | - | - | 100% | - |
| Operating Expenses | 50.96M | 76.26M | 68.15M | 55.27M | 55.09M | 32.71M | 9.07M | 9.35M | 32.07M | 46.43M | 58.44M | 47.62M | 23.55M | 19.54M | 12.06M |
| OpEx % of Revenue | - | 40138.95% | 28999.57% | 15657.79% | 530.47% | - | 86.8% | 2216.11% | - | - | - | - | - | - | - |
| Selling, General & Admin | 17.76M | 17.6M | 13.78M | 12.98M | 12.29M | 10.75M | 9.07M | 9.35M | 11.69M | 16.36M | 14.19M | 13.11M | 6.78M | 5.71M | 4.31M |
| SG&A % of Revenue | - | 9262.11% | 5862.55% | 3676.77% | 118.3% | - | 86.8% | 2216.11% | - | - | - | - | - | - | - |
| Research & Development | 55.72M | 60.22M | 54.37M | 42.29M | 42.81M | 23.26M | 17.29M | 14.05M | 20.39M | 30.07M | 44.25M | 34.5M | 16.78M | 13.83M | 7.75M |
| R&D % of Revenue | - | 31694.21% | 23137.02% | 11981.02% | 412.17% | - | 165.38% | 3328.91% | - | - | - | - | - | - | - |
| Other Operating Expenses | -1.39M | -1.55M | 0 | 0 | 0 | -1.3M | -17.29M | -14.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -73.29M | -77.63M | -67.91M | -54.92M | -46.4M | -34.02M | -15.91M | -22.98M | -32.82M | -47.15M | -59.34M | -47.62M | -23.55M | -19.54M | -12.6M |
| Operating Margin % | -38573.68% | -40856.32% | -28899.57% | -15557.79% | -446.79% | - | -152.19% | -5445.02% | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -14.3% | -23.66% | -18.35% | -36.42% | -113.78% | 30.76% | 29.99% | 30.39% | 20.55% | -24.62% | -102.16% | -20.53% | -55.11% | - |
| EBITDA | -71.95M | -76.07M | -66.37M | -52.18M | -44.71M | -32.71M | -14.64M | -22.34M | -32.07M | -46.43M | -58.44M | -46.75M | -22.73M | -18.83M | -12.06M |
| EBITDA Margin % | -37868.42% | -40038.95% | -28244.26% | -14781.3% | -430.47% | - | -140.08% | -5294.55% | - | - | - | - | - | - | - |
| EBITDA Growth % | -9.48% | -14.61% | -27.21% | -16.71% | -36.68% | -123.36% | 34.45% | 30.34% | 30.92% | 20.55% | -25.01% | -105.71% | -20.7% | -56.13% | - |
| D&A (Non-Cash Add-back) | 1.34M | 1.55M | 1.54M | 2.74M | 1.7M | 1.3M | 1.27M | 635K | 746K | 713K | 900K | 869K | 829K | 714K | 540K |
| EBIT | -72.29M | -77.63M | -67.91M | -54.92M | -46.4M | -33.78M | -15.91M | -22.98M | -34.52M | -47.15M | -57.94M | -46.22M | -23.55M | -19.54M | -12.59M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -832K | -444K | -272K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 65K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 832K | 444K | 272K |
| Other Income/Expense | 3.26M | 3.51M | 3.89M | 4.52M | 1.06M | 238K | -319K | -785K | -1.7M | -1.06M | 1.44M | -357K | -796K | -472K | -261K |
| Pretax Income | -70.03M | -74.12M | -64.02M | -50.4M | -45.34M | -33.78M | -16.23M | -23.76M | -34.52M | -48.21M | -57.9M | -47.97M | -24.35M | -20.01M | -12.86M |
| Pretax Margin % | -36859.47% | -39009.47% | -27243.4% | -14276.77% | -436.58% | - | -155.24% | -5631.04% | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -49K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.08% | 0% | 0% | 0% | 0% |
| Net Income | -70.03M | -74.12M | -64.02M | -50.39M | -45.34M | -33.77M | -16.22M | -23.6M | -34.52M | -48.21M | -57.85M | -47.97M | -24.35M | -20.01M | -17.61M |
| Net Margin % | -36857.37% | -39009.47% | -27243.83% | -14274.5% | -436.53% | - | -155.18% | -5593.13% | - | - | - | - | - | - | - |
| Net Income Growth % | -10.43% | -15.77% | -27.06% | -11.14% | -34.26% | -108.14% | 31.26% | 31.62% | 28.4% | 16.68% | -20.6% | -97.01% | -21.66% | -13.66% | - |
| Net Income (Continuing) | -70.03M | -74.12M | -64.02M | -50.4M | -45.34M | -33.78M | -16.23M | -23.76M | -34.52M | -48.21M | -57.85M | -47.97M | -24.35M | -20.01M | -12.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -193K | -192K | -187K | -188K | -180K | -175K | -166K | -160K | 0 | 0 | 0 | 0 | 0 | 2.41M | 25K |
| EPS (Diluted) | -0.71 | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 | -16.13 | -26.16 | -34.20 | -42.42 | -415.63 | -397.39 | -0.45 |
| EPS Growth % | 9.88% | 6.98% | 8.51% | 41.25% | 9.6% | 0% | 74.82% | 56.42% | 38.34% | 23.51% | 19.38% | 89.79% | -4.59% | -88208.89% | - |
| EPS (Basic) | - | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 | -16.13 | -26.16 | -34.20 | -42.42 | -422.73 | -429.90 | -0.45 |
| Diluted Shares Outstanding | 98.04M | 92.99M | 74.26M | 53.61M | 28.42M | 19.08M | 9.16M | 3.36M | 2.14M | 1.84M | 1.69M | 1.13M | 59.59K | 54.48K | 39.42M |
| Basic Shares Outstanding | 98.04M | 92.99M | 74.26M | 53.61M | 28.42M | 19.08M | 9.16M | 3.36M | 2.14M | 1.84M | 1.69M | 1.13M | 58.59K | 50.36K | 39.42M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Binary clinical trial failure
As indicated by the company's financial statements, revenue remains sporadic and entirely dependent on non-recurring milestone payments, with no consistent top-line growth trajectory observed over the last ten quarters as the firm continues to operate without a commercialized product in its portfolio.
The absence of a recurring revenue stream underscores the company's status as a purely clinical-stage entity. Investors should note that the intermittent inflows are tied to specific partnership milestones rather than market demand, rendering traditional growth analysis inapplicable.
Based on reported figures, the company's cost structure is heavily skewed toward research and development, with quarterly R&D expenses frequently exceeding $10 million, reflecting the significant capital intensity required to advance the EFZO-FIT Phase III clinical trial toward potential regulatory submission.
The high R&D burn rate is a structural necessity for a firm at this stage of development. Management's expense discipline is difficult to assess given that these costs are essentially mandatory investments in the company's primary intangible asset, the efzofitimod platform.
According to recent SEC filings, the company consistently reports deeply negative operating margins, with quarterly losses often exceeding $15 million, which highlights the lack of operating leverage inherent in a business model that has yet to achieve any meaningful scale or commercial revenue.
The widening gap between R&D spending and nominal revenue suggests that the firm is currently in a phase of maximum cash consumption. Without a transition to commercialization, these operating losses will likely persist, necessitating ongoing external financing to sustain operations.
As reported in financial statements, the company's cash position of $10.7 million appears critically low relative to its historical quarterly burn rate, suggesting that the firm may face an imminent need for dilutive capital to maintain its current clinical development timeline.
Short-sellers would likely focus on this precarious liquidity position, which leaves little room for error in clinical trial execution or partnership negotiations. The reliance on future milestone payments creates a high-risk profile where any delay in trial progress could severely impair the company's financial flexibility.
Quick answers to the most common questions about buying ATYR stock.
For fiscal year 2025, aTyr Pharma, Inc. (ATYR) reported total revenue of $0.2M.
aTyr Pharma, Inc. (ATYR) reported a net loss of $74.1M for the fiscal year ending 2025.
aTyr Pharma, Inc. (ATYR) reported an operating income of $-77.6M, resulting in an operating profit margin of -40856.3%. This margin reflects the operational efficiency of the business before interest and taxes.
aTyr Pharma, Inc. (ATYR) generated $-1.4M in gross profit for the year, representing a gross profit margin of -717.4%. This demonstrates the company's core pricing power and production efficiency.